S. thermophilus

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion immunity inflammation

Research Overview

Research on Streptococcus thermophilus has been most extensive in food microbiology and dairy technology, reflecting its long-standing role as a yogurt/fermented milk starter. Commonly studied areas include fermentation performance (acidification kinetics, post-acidification during storage), interactions and symbiosis with Lactobacillus delbrueckii ssp. bulgaricus (e.g., how inoculum ratios affect pH trajectories, texture/rheology, and volatile flavor profiles), and strain-dependent production traits such as extracellular polysaccharides (EPS) that influence viscosity and mouthfeel. In parallel, comparative genomics across dozens of strains has become a major research theme, mapping conserved functions (e.g., lactose utilization, folate production) versus strain-specific pathways (e.g., galactose catabolism routes, bioactive peptide and GABA production), and assessing safety-relevant features such as the generally low prevalence of biogenic amine and antibiotic resistance genes.

The strongest evidence base supports S. thermophilus as a safe, effective industrial starter with predictable technological benefits that are highly strain- and consortium-dependent (notably in co-culture with L. bulgaricus). Genomic surveys reinforce that some potentially health-relevant metabolic capacities are widespread (e.g., lactose degradation; folate biosynthesis in many strains), while other putative benefits are not universal and likely depend on horizontal gene transfer and regulatory variation. Emerging experimental evidence also supports bioactivity beyond fermentation: cell-free supernatants from certain strains can inhibit pathogen biofilm formation in vitro, and one mouse-model study reports reduced intestinal tumor formation with oral administration, implicating secreted β-galactosidase as a mediator. However, these latter findings are currently strongest at the preclinical/mechanistic level rather than as established clinical effects in humans.

Key gaps include translation of strain-specific genomic potential into validated, reproducible human health outcomes. More research is needed to (i) determine which strains and doses reliably survive gastrointestinal transit and exert measurable effects in vivo; (ii) establish causality and mechanisms for proposed benefits (e.g., anti-biofilm metabolites, immunomodulation, or anti-tumor activity) using standardized models and well-controlled interventions; and (iii) conduct adequately powered human trials for specific indications (including adjunctive roles in infections such as H. pylori and potential cancer-preventive effects suggested by metagenomic associations and mouse studies). Additional priorities are improved characterization of EPS structures and their functional consequences, and clearer links between starter design (e.g., directed-vat-set formulations, cryoprotection, consortium ratios) and both product quality and any downstream health-relevant bioactivity.

1. What conditions has S. thermophilus been studied for?

  • Colorectal cancer (CRC) prevention / intestinal tumorigenesis (preclinical): Identified as depleted in CRC patients in a multicohort fecal metagenomics dataset (526 samples), then tested for prophylaxis in cell and mouse models of intestinal tumorigenesis.

  • Helicobacter pylori treatment support (pediatrics, as part of probiotic combinations): Evaluated within probiotic-supplemented triple therapy trials/meta-analysis; S. thermophilus appears in several multi-strain regimens aimed at improving eradication rates and reducing side effects.

  • Antibiofilm/anti-pathogen potential (in vitro/ex vivo style evidence): Strains from homemade/commercial dahi studied for probiotic traits and for cell-free supernatants reducing pathogenic biofilm formation; metabolites characterized by GC-MS and assessed in silico for “drug-like” properties.

  • Exercise-associated inflammation / immunomodulation (human trial context, incomplete abstract): Probiotics (not necessarily S. thermophilus alone) studied for effects on inflammation after strenuous exercise; the provided abstract is truncated so strain/species-specific conclusions can’t be made from it.

  • Lactose digestion-related functionality (mechanistic/functional): Genomic survey notes lactose degradation as a widely conserved function; CRC mouse study implicates secreted β-galactosidase (lactase activity) as a mediator of tumor-suppressive effects.

2. Does it work in treating those conditions? Summarize the evidence.

  • CRC prevention (mouse models): supportive preclinical evidence. Oral gavage of S. thermophilus “significantly reduced tumor formation” in two murine models of intestinal tumorigenesis. The authors identify a secreted tumor-suppressive protein as β-galactosidase (supported by mass spectrometry and β-galactosidase activity assay), and they constructed a mutant strain via homologous recombination to interrogate mechanism. This supports a causal, mechanistic effect in mice, but it is not human clinical evidence.

  • H. pylori eradication (children): evidence supports probiotics as an adjunct, but S. thermophilus-specific efficacy is unclear. A network meta-analysis of 29 trials (3122 participants) found probiotic-supplemented triple therapy improved eradication rates vs placebo (RR 1.19, 95% CI 1.13–1.25) and reduced total side effects (RR 0.49, 95% CI 0.38–0.65). However, the “best” regimens for eradication and overall side effects were not centered on S. thermophilus alone; S. thermophilus appears in certain multi-strain combinations that ranked best for specific side effects (e.g., diarrhea; constipation; nausea/vomiting). Because these are multi-strain regimens, the independent contribution of S. thermophilus cannot be isolated from the abstract.

  • Biofilm-related outcomes: preliminary. Dahi-derived S. thermophilus strains’ cell-free supernatants reduced biofilm formation of pathogenic bacteria; metabolites (e.g., 2,4-di-tert-butylphenol shared; 2-butanol unique to one strain) were identified and assessed in silico. This is hypothesis-generating and does not establish clinical treatment efficacy.

Overall: strongest evidence in the provided abstracts is preclinical CRC prophylaxis and adjunctive benefit of probiotics (including some regimens containing S. thermophilus) in pediatric H. pylori therapy. Human evidence for S. thermophilus as a single-agent treatment is not established from these abstracts.

3. What health benefits does it have?

  • Potential CRC-protective activity (preclinical): In mice, reduced intestinal tumor formation; effect “mediated at least” by secreted β-galactosidase. The study also assessed gut microbiota composition via shotgun metagenomics, suggesting microbiome-level effects may be involved (details not fully shown in the excerpt).

  • Digestive functionality (lactose-related): Comparative genomics across 79 strains found lactose degradation is widely conserved; β-galactosidase secretion is also highlighted in the CRC study (a lactase-type activity), which is biologically consistent with supporting lactose breakdown.

  • Micronutrient and bioactive compound potential (strain-dependent): The 79-genome analysis reports some functions are widely conserved (e.g., folate production), while others are strain-specific (e.g., production of bioactive peptides and gamma-aminobutyric acid (GABA)), implying benefits depend heavily on the exact strain used.

  • Adjunctive GI tolerability during antibiotics (multi-strain evidence): In pediatric H. pylori triple therapy, probiotic supplementation reduced overall side effects; multi-strain regimens including S. thermophilus ranked best for certain symptoms (e.g., diarrhea reduction in one multi-strain mix; constipation reduction in a B. longum + L. bulgaricus + S. thermophilus mix; nausea/vomiting reduction in another multi-strain mix).

  • Antibiofilm potential (strain products): Cell-free supernatants from dahi-derived strains reduced pathogenic biofilm formation; this suggests a possible role in limiting pathogen persistence, though clinical relevance is unproven from the abstract.

  • Food/fermentation-related benefits that can indirectly support intake/acceptability: Coculture work with L. delbrueckii ssp. bulgaricus found an optimal inoculum ratio (19:1) improved acidification activity, rheology, volatile compounds, and sensory quality, with relatively stable pH during storage—relevant to delivering viable cultures in palatable foods.

4. Does it have any downsides or side effects?

  • Generally favorable safety signals at the genomic level: The comparative genomics study notes a low occurrence of genes coding for biogenic amine production and antibiotic resistance, which supports its safety status (but does not replace clinical safety data for specific strains/products).

  • Side effects context (as part of probiotic regimens): In pediatric H. pylori therapy, probiotics overall reduced side effects (RR 0.49). The abstract does not report S. thermophilus causing adverse effects; rather, regimens including it were associated with reduced GI side effects in some rankings. Because these are combinations, safety attribution to S. thermophilus alone is limited.

  • Strain variability is a practical downside: Multiple abstracts emphasize substantial intra-species diversity (health-related traits can be strain-specific and sometimes acquired via horizontal gene transfer). This means benefits and risks may not generalize across all S. thermophilus strains.

  • Food technology issues (not human toxicity, but product quality): In fermented milk systems, post-acidification during storage can occur; one study linked ongoing acetic acid accumulation with postacidification in certain cultures. This is mainly a quality/tolerability consideration (taste/acid load) rather than a direct safety signal.

Important limitation: the provided abstracts do not describe rates of adverse events for S. thermophilus as a single-strain supplement in humans, nor do they address rare-risk populations (e.g., severe immunocompromise).

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

  • No direct human pharmacogenomic findings are provided: None of the abstracts report outcomes stratified by human genetic variants (e.g., lactase persistence genotype, immune polymorphisms) or gene–probiotic interactions.

  • Relevant microbial “genetics” (strain genomics) strongly affects function: The 79-genome analysis shows some health-related pathways are conserved (lactose degradation, folate production) while others are strain-specific (GABA, bioactive peptides, tagatose-6-phosphate pathway for galactose; Leloir pathway differences linked to galK promoter substitutions). This is not pharmacogenomics in the human sense, but it is highly relevant to predicting who may benefit based on the exact strain used.

  • Mechanistic hint that could intersect with human genetics (not tested): The CRC mouse study implicates secreted β-galactosidase. Hypothetically, this could interact with host lactose-digestion capacity, but the abstracts do not test genotype-dependent effects.

Bottom line: based on these abstracts, there is no evidence that S. thermophilus is specifically beneficial or harmful for particular human genetic variants; the clearest “genetic” determinant of effects is the bacterial strain’s genome.

References

  1. Streptococcus thermophilus Inhibits Colorectal Tumorigenesis Through Secreting β-Galactosidase.
    Qing Li, Wei Hu, Wei-Xin Liu, Liu-Yang Zhao, Dan Huang, Xiao-Dong Liu, Hung Chan, Yuchen Zhang, Ju-Deng Zeng, Olabisi Oluwabukola Coker, Wei Kang, Simon Siu Man Ng, Lin Zhang, Sunny Hei Wong, Tony Gin, Matthew Tak Vai Chan, Jian-Lin Wu, Jun Yu, William Ka Kei Wu (2021) - Gastroenterology
  2. Beneficial Effects of Yoghurts and Probiotic Fermented Milks and Their Functional Food Potential.
    Elena Hadjimbei, George Botsaris, Stavrie Chrysostomou (2022) - Foods (Basel, Switzerland)
  3. Structural elucidation of the exopolysaccharide from Streptococcus thermophilus XJ53 and the effect of its molecular weight on immune activity.
    Wei Xia, Jin Han, Shiming Zhu, Yilin Wang, Wenqing Zhang, Zhengjun Wu (2023) - International journal of biological macromolecules
  4. Fermentation characteristics and postacidification of yogurt by Streptococcus thermophilus CICC 6038 and Lactobacillus delbrueckii ssp. bulgaricus CICC 6047 at optimal inoculum ratio.
    Yuanyuan Ge, Xuejian Yu, Xiaoxin Zhao, Chong Liu, Ting Li, Shuaicheng Mu, Lu Zhang, Zhuoran Chen, Zhe Zhang, Zhiquan Song, Hongfei Zhao, Su Yao, Bolin Zhang (2024) - Journal of dairy science
  5. The genomic basis of the Streptococcus thermophilus health-promoting properties.
    Emeline Roux, Aurélie Nicolas, Florence Valence, Grégoire Siekaniec, Victoria Chuat, Jacques Nicolas, Yves Le Loir, Eric Guédon (2022) - BMC genomics
  6. New Insights into Various Production Characteristics of Streptococcus thermophilus Strains
    Yanhua Cui, Tingting Xu, Xiaojun Qu, Tong Hu, Xu Jiang (2016)
  7. Comprehensive genomics, probiotic, and antibiofilm potential analysis of Streptococcus thermophilus strains isolated from homemade and commercial dahi.
    Aiswarya Sudheer, Debabrata Ghosh Dastidar, Gourav Ghosh, Zarin Taj, Illathu Kandy Nidhin, Indranil Chattopadhyay (2025) - Scientific reports
  8. Effect of freeze-dried protectants on the survival rate and fermentation performance of fermented milk's directed vat set starters.
    Yue Tian, Zuyan He, Laping He, Cuiqin Li, Shunbin Qiao, Han Tao, Xiao Wang, Xuefeng Zeng, Yun Tian (2024) - Cryobiology
  9. Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis.
    Jue-Rong Feng, Fan Wang, Xiao Qiu, Lynne V McFarland, Peng-Fei Chen, Rui Zhou, Jing Liu, Qiu Zhao, Jin Li (2017) - European journal of clinical pharmacology
  10. Selective and differential enumerations of Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, Lactobacillus acidophilus, Lactobacillus casei and Bifidobacterium spp. in yoghurt--a review.
    Rabia Ashraf, Nagendra P Shah (2011) - International journal of food microbiology
  11. Probiotic Streptococcus thermophilus FP4 and Bifidobacterium breve BR03 Supplementation Attenuates Performance and Range-of-Motion Decrements Following Muscle Damaging Exercise.
    Ralf Jäger, Martin Purpura, Jason D Stone, Stephanie M Turner, Anthony J Anzalone, Micah J Eimerbrink, Marco Pane, Angela Amoruso, David S Rowlands, Jonathan M Oliver (2016) - Nutrients
  12. Understanding the bacterial communities of hard cheese with blowing defect.
    Daniela Bassi, Edoardo Puglisi, Pier Sandro Cocconcelli (2015) - Food microbiology
  13. Influence of Hesperidin on the Physico-Chemical, Microbiological and Sensory Characteristics of Frozen Yogurt.
    Roberto Cedillos, Ricardo S Aleman, Ryan Page, Douglas W Olson, Charles Boeneke, Witoon Prinyawiwatkul, Kayanush Aryana (2024) - Foods (Basel, Switzerland)
  14. Yogurt starter cultures of Streptococcus thermophilus and Lactobacillus bulgaricus ameliorate symptoms and modulate the immune response in a mouse model of dextran sulfate sodium-induced colitis.
    E Wasilewska, D Zlotkowska, B Wroblewska (2019) - Journal of dairy science
  15. Dietary whey protein protects against Crohn's disease by orchestrating cross-kingdom interaction between the gut phageome and bacteriome.
    Runping Su, Weijie Wen, Yufeng Jin, Zhirui Cao, Zhiyang Feng, Jie Chen, Yu Lu, Guicheng Zhou, Chao Dong, Shanshan Gao, Xue Li, Hu Zhang, Kang Chao, Ping Lan, Xiaojian Wu, Anna Philips, Kun Li, Xiang Gao, Fen Zhang, Tao Zuo (2025) - Gut
  16. New advances in exopolysaccharides production of Streptococcus thermophilus.
    Yanhua Cui, Xu Jiang, Mengyuan Hao, Xiaojun Qu, Tong Hu (2017) - Archives of microbiology
  17. Impact of long-term dietary habits on the human gut resistome in the Dutch population.
    Paul B Stege, Joost Hordijk, Sudarshan A Shetty, Michael Visser, Marco C Viveen, Malbert R C Rogers, Esther Gijsbers, Cindy M Dierikx, Rozemarijn Q J van der Plaats, Engeline van Duijkeren, Eelco Franz, Rob J L Willems, Susana Fuentes, Fernanda L Paganelli (2022) - Scientific reports
  18. Streptococcus thermophilus Attenuates Inflammation in Septic Mice Mediated by Gut Microbiota.
    Fu Han, Gaofeng Wu, Yijie Zhang, Haotian Zheng, Shichao Han, Xiaoqiang Li, Weixia Cai, Jiaqi Liu, Wanfu Zhang, Xiaowei Zhang, Dahai Hu (2020) - Frontiers in microbiology
  19. In vitro Probiotic Potential and Anti-cancer Activity of Newly Isolated Folate-Producing Streptococcus thermophilus Strains.
    Armin Tarrah, Juliana de Castilhos, Rochele Cassanta Rossi, Vinicius da Silva Duarte, Denize Righetto Ziegler, Viviana Corich, Alessio Giacomini (2018) - Frontiers in microbiology
  20. Development and characterization of an innovative synbiotic fermented beverage based on vegetable soybean.
    Carolina Battistini, Beatriz Gullón, Erica Sayuri Ichimura, Ana Maria Pereira Gomes, Eliana Paula Ribeiro, Leo Kunigk, José Ubirajara Vieira Moreira, Cynthia Jurkiewicz (2018) - Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!